Infliximab is effective in the treatment of ulcerative colitis with dermatomyositis: A case report.
Infliximab is effective in the treatment of ulcerative colitis with dermatomyositis: A case report.
复制标题
英夫利昔单抗治疗溃疡性结肠炎伴皮肌炎有效：一例报告
DOI：
10.3748/wjg.v26.i46.7425
复制
发表时间：
2020-12-14
影响因子：
4.3
通讯作者：
Lv XP
中科院分区：
文献类型：
--
作者：
Huang BB;Han LC;Liu GF;Lv XD;Gu GL;Li SQ;Chen L;Wang HQ;Zhan LL;Lv XP
背景：关节、皮肤、口腔和眼部病变是溃疡性结肠炎最常见的肠外表现，可发生在发病前或发病后。溃疡性结肠炎合并皮肌炎的病例比较少见。在这项研究中，我们报告了一例罕见的溃疡性结肠炎合并糖尿病的病例，该病例经英夫利西单抗有效治疗。病例总结患者为57岁女性，有2年DM病史。患者因腹痛、腹泻和便血持续2个月以上入院。结肠镜检查显示整个结肠和直肠有多处糜烂和溃疡。病理切片显示结肠粘膜慢性炎性细胞浸润，尤其是中性粒细胞浸润;因此，患者被诊断为溃疡性结肠炎。在治疗DM的基础上加用5-氨基水杨酸制剂，但效果不理想。患者接受英夫利西单抗治疗后不适缓解。结论英夫利西单抗治疗溃疡性结肠炎可改善DM的疗效。专家需要提高对患有炎症性肠病的患者的认识，这些患者具有罕见的肠外表现。
BACKGROUND Joint, skin, oral cavity, and eye lesions are the most common extraintestinal manifestations of ulcerative colitis that can occur before or after its onset. The cases of ulcerative colitis with dermatomyositis (DM) are rare. In this study, we report a rare case of ulcerative colitis with DM that was effectively treated with infliximab. CASE SUMMARY The patient was a 57-year-old female with a 2-year history of DM. The patient was admitted to hospital with abdominal pain, diarrhea, and blood in stool lasting for more than 2 mo. Colonoscopy revealed multiple erosions and ulcers in the entire colon and rectum. Pathological sections showed chronic inflammatory cell infiltration, especially neutrophil infiltration, in the colonic mucosa; therefore, the patient was diagnosed with ulcerative colitis. Preparations of 5-aminosalicylic acid was added to her treatment based on the original treatment for DM, but its effect was unsatisfactory. The patient’s discomfort was relieved after infliximab treatment. CONCLUSION Infliximab can improve DM in the treatment of ulcerative colitis. Specialists need to raise awareness about patients with inflammatory bowel disease who have rare extraintestinal manifestations.
登录
查看更多内容
影响因子：
5
作者：
Schiffenbauer A;Garg M;Castro C;Pokrovnichka A;Joe G;Shrader J;Cabalar IV;Faghihi-Kashani S;Harris-Love MO;Plotz PH;Miller FW;Gourley M
通讯作者：
Gourley M
影响因子：
15.8
作者：
McGonagle D;McDermott MF
通讯作者：
McDermott MF
影响因子：
4.9
作者：
Vavricka SR;Schoepfer A;Scharl M;Lakatos PL;Navarini A;Rogler G
通讯作者：
Rogler G
影响因子：
24.5
作者：
Satsangi, J.;Silverberg, M. S.;Colombel, J-F
通讯作者：
Colombel, J-F
影响因子：
3.1
作者：
Tweezer-Zaks, Nurit;Ben-Horin, Shomron;Langevitz, Pnina
通讯作者：
Langevitz, Pnina